This research demonstrates improved pharmacokinetics and efficacy in prostate cancer using a modified peptide-drug conjugate, suggesting potential for enhanced treatment.
Prostate-specific membrane antigen (PSMA)-targeting peptide-drug conjugates (PDCs) offer promise for the treatment of PSMA-positive prostate cancer, but their applications are limited by rapid clearance, poor pharmacokinetics, and low efficacy. Herein,...
No takes yet. Share an insight, caveat, or question.
QIU et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: